CNMD vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CNMD exhibits a stark divergence between its strong balance sheet health (Piotroski F-Score: 7/9) and its deteriorating operational performance. While the company maintains a stable financial foundation and a low Price-to-Sales ratio, it is plagued by a severe earnings collapse (-50% YoY) and a consistent track record of missing analyst estimates (0/4 beats in the last year). With the current price ($38.34) trading above the Graham Number ($33.66) and significantly above the growth-based intrinsic value ($10.57), the stock lacks a valuation catalyst despite a low forward P/E.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
CNMD vs MRK: Head-to-Head Comparison
This page compares CONMED Corporation (CNMD) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.